Transgene

Transgene FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Transgene (TNG.PA) as of Oct 8, 2026 is 78.34 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 167.23 % — a change of -53.15% (lower).

FCF Conversion

78.34 %

YoY

-53.15%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Transgene is 2024 78.34 % . FCF Conversion Rate (FCF/EBITDA) of Transgene was 2023 167.23 % . It decreases by -53.15% lower compared to the previous year.

The Transgene FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
110.93 EUR
Jan 1, 2018
-370.55 EUR
Jan 1, 2019
128.17 EUR
Jan 1, 2020
171.51 EUR
Jan 1, 2021
136.06 EUR
Jan 1, 2022
66.46 EUR
Jan 1, 2023
167.23 EUR
Jan 1, 2024
78.34 EUR
The Transgene FCF Conversion history
YEARFCF ConversionYoY
78.34 %-53.15%
167.23 %+151.64%
66.46 %-51.16%
136.06 %-20.67%
171.51 %+33.82%
128.17 %-134.59%
-370.55 %-434.03%
110.93 %-16.81%
133.34 %+32.47%
100.66 %-13.80%
116.77 %—
Access this data via the Eulerpool API

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

FCF Conversion Rate (FCF/EBITDA) of Transgene is 78.34 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of Transgene changed from 167.23 % to 78.34 %, representing a -53.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Transgene since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Transgene with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Transgene

All Key Metrics — Transgene